CN116096705A - 新型化合物 - Google Patents
新型化合物 Download PDFInfo
- Publication number
- CN116096705A CN116096705A CN202180053567.3A CN202180053567A CN116096705A CN 116096705 A CN116096705 A CN 116096705A CN 202180053567 A CN202180053567 A CN 202180053567A CN 116096705 A CN116096705 A CN 116096705A
- Authority
- CN
- China
- Prior art keywords
- acrylamide
- methyl
- alkyl
- dihydro
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/32—Oxygen atoms
- C07D209/34—Oxygen atoms in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/96—Spiro-condensed ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/26—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/16—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
- C07D249/18—Benzotriazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB2013728.7 | 2020-09-01 | ||
| GBGB2013728.7A GB202013728D0 (en) | 2020-09-01 | 2020-09-01 | Novel compounds |
| PCT/GB2021/052261 WO2022049376A1 (en) | 2020-09-01 | 2021-09-01 | Novel compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116096705A true CN116096705A (zh) | 2023-05-09 |
Family
ID=72749708
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202180053567.3A Pending CN116096705A (zh) | 2020-09-01 | 2021-09-01 | 新型化合物 |
Country Status (12)
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB202013731D0 (en) | 2020-09-01 | 2020-10-14 | Nrg Therapeutics Ltd | Novel cmpounds |
| WO2023209651A1 (en) * | 2022-04-29 | 2023-11-02 | Dong-A St Co., Ltd. | Bicycle compounds as tead inhibitor |
| GB202300833D0 (en) | 2023-01-19 | 2023-03-08 | Nrg Therapeutics Ltd | Novel compounds |
| CN119306612B (zh) * | 2023-07-14 | 2026-03-20 | 中国科学院大连化学物理研究所 | 一种反式氨基茚满的制备方法 |
| CN121866248A (zh) | 2023-09-05 | 2026-04-14 | Nrg治疗有限公司 | 作为mptp抑制剂起作用的吡啶衍生物 |
| GB202410534D0 (en) | 2024-07-18 | 2024-09-04 | Nrg Therapeutics Ltd | Novel method and uses |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4948796A (en) * | 1988-03-03 | 1990-08-14 | Toyama Chemical Co., Ltd. | Piperazine derivative or its salt, process for producing the same and pharmaceutical composition comprising the same as active ingredient |
| WO2004037751A2 (en) * | 2002-08-29 | 2004-05-06 | Temple University - Of The Commonwealth System Of Higher Education | Aryl and heteroaryl propene amides, derivatives thereof and therapeutic uses thereof |
| JP2006160916A (ja) * | 2004-12-08 | 2006-06-22 | Fuji Photo Film Co Ltd | インクジェット用インク組成物及びインクジェット記録方法 |
| CN102264693A (zh) * | 2008-10-27 | 2011-11-30 | 康金尼亚有限公司 | 用作线粒体通透性转变抑制剂的丙烯酰胺衍生物 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPWO2003020313A1 (ja) | 2001-09-04 | 2004-12-16 | 小野薬品工業株式会社 | スフィンゴシン−1−リン酸受容体調節剤からなる呼吸器疾患治療剤 |
| AU2002354476A1 (en) | 2001-12-14 | 2003-06-30 | Japan Tobacco Inc. | Pyrazolopyridine derivatives and medicinal use thereof |
| JP5495206B2 (ja) | 2006-10-24 | 2014-05-21 | コンジエニア・ソシエタ・ア・レスポンサビリタ・リミタータ | 変性性組織障害をmptの阻害により防止するための薬剤としてのフェニル置換マレイミド |
| WO2011087051A1 (ja) | 2010-01-14 | 2011-07-21 | 国立大学法人金沢大学 | S1p2受容体アンタゴニストを含む粥状動脈硬化治療薬 |
| JP5990106B2 (ja) | 2011-01-28 | 2016-09-07 | 佐藤製薬株式会社 | 縮環化合物 |
| JP2017538676A (ja) | 2014-11-05 | 2017-12-28 | ザ ユニバーシティ オブ カンザス | ミトコンドリア透過性遷移孔(mtPTP)の小分子阻害剤 |
| WO2016090371A2 (en) | 2014-12-05 | 2016-06-09 | An2H Discovery Limited | Parkin ligase activation methods and compositions |
| CA2884607A1 (en) | 2015-03-11 | 2016-09-11 | Stealth Peptides International, Inc. | Therapeutic compositions including acrylamido compounds or phenyl-substiituted maleimide compounds and uses thereof to treat and prevent mitochondrial diseases and conditions |
| WO2019002624A1 (de) | 2017-06-30 | 2019-01-03 | Kleuser, Burkhard | Mittel zur therapie entzündlicher darmerkrankungen |
| GB202013731D0 (en) | 2020-09-01 | 2020-10-14 | Nrg Therapeutics Ltd | Novel cmpounds |
-
2020
- 2020-09-01 GB GBGB2013728.7A patent/GB202013728D0/en not_active Ceased
-
2021
- 2021-09-01 MX MX2023002525A patent/MX2023002525A/es unknown
- 2021-09-01 CN CN202180053567.3A patent/CN116096705A/zh active Pending
- 2021-09-01 US US18/023,558 patent/US12630516B2/en active Active
- 2021-09-01 IL IL300900A patent/IL300900A/en unknown
- 2021-09-01 ES ES21769789T patent/ES3055772T3/es active Active
- 2021-09-01 EP EP21769789.5A patent/EP4208442B1/en active Active
- 2021-09-01 AU AU2021337195A patent/AU2021337195A1/en not_active Abandoned
- 2021-09-01 KR KR1020237007646A patent/KR20230069915A/ko not_active Withdrawn
- 2021-09-01 JP JP2023537723A patent/JP7784430B2/ja active Active
- 2021-09-01 CA CA3190645A patent/CA3190645A1/en active Pending
- 2021-09-01 WO PCT/GB2021/052261 patent/WO2022049376A1/en not_active Ceased
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4948796A (en) * | 1988-03-03 | 1990-08-14 | Toyama Chemical Co., Ltd. | Piperazine derivative or its salt, process for producing the same and pharmaceutical composition comprising the same as active ingredient |
| WO2004037751A2 (en) * | 2002-08-29 | 2004-05-06 | Temple University - Of The Commonwealth System Of Higher Education | Aryl and heteroaryl propene amides, derivatives thereof and therapeutic uses thereof |
| US20060167317A1 (en) * | 2002-08-29 | 2006-07-27 | Temple University- Of The Commonwealth System Of Higher Education | Aryl and heteroaryl propene amides, derivatives thereof and therapeutic uses thereof |
| JP2006160916A (ja) * | 2004-12-08 | 2006-06-22 | Fuji Photo Film Co Ltd | インクジェット用インク組成物及びインクジェット記録方法 |
| CN102264693A (zh) * | 2008-10-27 | 2011-11-30 | 康金尼亚有限公司 | 用作线粒体通透性转变抑制剂的丙烯酰胺衍生物 |
Non-Patent Citations (5)
| Title |
|---|
| DANIELE FANCELLI等: "Cinnamic Anilides as New Mitochondrial Permeability Transition Pore Inhibitors Endowed with Ischemia-Reperfusion Injury Protective Effect in Vivo", 《JOURNAL OF MEDICINAL CHEMISTRY》, vol. 57, 11 June 2014 (2014-06-11), pages 5333, XP055464404, DOI: 10.1021/jm500547c * |
| MAO XIANG CHEN等: "Probing Mitochondrial Permeability Transition Pore Activity in Nucleated Cells and Platelets by High-Throughput Screening Assays Suggests Involvement of Protein Phosphatase 2B in Mitochondrial Dynamics", 《ASSAY AND DRUG DEVELOPMENT TECHNOLOGIES》, vol. 16, no. 8, 1 December 2018 (2018-12-01), pages 3, XP055848095, DOI: 10.1089/adt.2018.872 * |
| STN,REGISRY: "CAS RN:1268319-90-9", 《STN,REGISRY》, 13 March 2011 (2011-03-13) * |
| STN,REGISRY: "CAS RN:2362016-29-1", 《STN,REGISRY》, 30 July 2019 (2019-07-30) * |
| STN,REGISRY: "CAS RN:76381-40-3、76381-39-0、76381-38-9", 《STN,REGISRY》, 13 March 2011 (2011-03-13) * |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023539694A (ja) | 2023-09-15 |
| WO2022049376A1 (en) | 2022-03-10 |
| JP7784430B2 (ja) | 2025-12-11 |
| US12630516B2 (en) | 2026-05-19 |
| MX2023002525A (es) | 2023-05-17 |
| KR20230069915A (ko) | 2023-05-19 |
| EP4208442B1 (en) | 2025-10-22 |
| EP4208442A1 (en) | 2023-07-12 |
| US20240067614A1 (en) | 2024-02-29 |
| ES3055772T3 (en) | 2026-02-16 |
| CA3190645A1 (en) | 2022-03-10 |
| GB202013728D0 (en) | 2020-10-14 |
| AU2021337195A1 (en) | 2023-03-02 |
| IL300900A (en) | 2023-04-01 |
| EP4208442C0 (en) | 2025-10-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN116096712B (zh) | 新型化合物 | |
| EP4208442B1 (en) | Mptp inhibitors | |
| EP2997023B9 (en) | Bipyrazole derivatives as jak inhibitors | |
| TW202136275A (zh) | 嗒𠯤基─噻唑甲醯胺化合物 | |
| CN118804911A (zh) | 丙烯酰胺化合物 | |
| CN113613649A (zh) | 用于治疗囊肿状纤维化的化合物及其治疗方法 | |
| CN120641407A (zh) | Mptp抑制剂 | |
| US20240247029A1 (en) | Interleukin-1 receptor modulators and uses thereof | |
| TWI570127B (zh) | 結晶型N-[3-[(4aR,7aS)-2-胺基-6-(5-氟嘧啶-2-基)-4,4a,5,7-四氫吡咯并[3,4-d][1,3]噻嗪-7a-基]-4-氟-苯基]-5-甲氧基-吡嗪-2-甲醯胺、其用途及醫藥組合物 | |
| WO2026018015A2 (en) | Novel methods and uses | |
| HK40012259A (en) | Bipyrazole derivatives as jak inhibitors | |
| HK1221466B (en) | Bipyrazole derivatives as jak inhibitors | |
| NZ753637B2 (en) | Bipyrazole derivatives as jak inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |